FDA lifts hold on Finch’s microbiome crapsule, as company looks to right ship

Finch Therapeutics’ lead program may fly again.

The microbiome company announced Thursday that the FDA lifted a two-month hold on clinical trials for its experimental treatment for recurrent C. diff, a potentially fatal bacterial infection. Although the company still has to take several steps before it can resume its pivotal study, the lift removes an unusual pandemic-related hurdle for Finch as the biotech looks to get its first therapy over the finish line and stabilize a precarious financial situation.